Inlyta 1mg Tablet

About

Inlyta 1mg Tablet, containing axitinib, is an oral tyrosine kinase inhibitor (TKI) specifically designed to target vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). By inhibiting these receptors, axitinib disrupts angiogenesis, the process of new blood vessel formation that tumors need to grow and spread. This targeted action helps to slow tumor progression and is primarily indicated for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. Its mechanism focuses on starving the tumor of its blood supply, thereby inhibiting its growth and metastatic potential, making it a crucial agent in targeted cancer therapy.

Uses

• Treatment of advanced renal cell carcinoma.
• Used after failure of one prior systemic therapy.
• Investigational use in other solid tumors.
• Part of combination therapies in clinical trials.

Directions For Use

Take orally with or without food, exactly as prescribed by your oncologist. Do not crush or chew the tablets.

Benefits

• Targets specific pathways involved in cancer growth.
• Improves progression-free survival in advanced RCC.
• Offers an oral administration route for convenience.
• Can be effective in patients resistant to other therapies.
• Manageable side effect profile with proper monitoring.
• Provides a targeted approach to cancer treatment.

Side Effects

• Hypertension (high blood pressure).
• Fatigue and asthenia.
• Diarrhea.
• Nausea and vomiting.
• Decreased appetite.
• Hand-foot syndrome (palmar-plantar erythrodysesthesia).
• Proteinuria (protein in urine).
• Headache.
• Dysphonia (hoarseness).
• Hypothyroidism.
• Abdominal pain.
• Weight loss.

Safety Measures

• Alcohol - Limit or avoid alcohol consumption as it may increase the risk of liver enzyme elevations and gastrointestinal irritation.
• Pregnancy - Inlyta is contraindicated during pregnancy due to potential for fetal harm. Women of childbearing potential must use effective contraception.
• Breastfeeding - Breastfeeding is not recommended during Inlyta treatment as it is unknown if axitinib is excreted in human milk, but potential for serious adverse reactions in infants exists.
• Liver - Use with caution in patients with liver impairment. Dose adjustments may be required for moderate to severe impairment, and liver function should be monitored.
• Kidney - Use with caution in patients with kidney impairment. No specific dose adjustment is generally needed for mild to moderate impairment, but monitor for proteinuria.
• Lung - Monitor for pulmonary events, including arterial thromboembolic events, though these are less common. Report any new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.